---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009826"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:32:35.810335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Passage Bio gets FDA green light to add FTD-C9orf72 arm to PBFT02 trial

## Summary
- Positive Type C meeting feedback from FDA supports evaluating PBFT02 in FTD-C9orf72 patients.
- Passage Bio to amend upliFT-D Phase 1/2 global study protocol to include FTD-C9orf72 population.
- Company plans to initiate dosing of FTD-C9orf72 patients in first half of 2025.
- FTD-C9orf72 affects an estimated 21,000 individuals in the U.S. and Europe.
- PBFT02 already has FDA Fast Track and Orphan Drug designations; also Orphan from European Commission.

## SEC filing metadata
- accession: 0001558370-24-009826
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837024009826/0001558370-24-009826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837024009826/pasg-20240716x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009826
- JSON: https://secwatch.observer/filing/0001558370-24-009826.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.